Search
Paul Anderson says Orthocell is well placed to further progress regulatory approvals for its products.

Orthocell to raise $18m

Bio-therapeutic company Orthocell has received commitments to raise $13 million from a share placement and up to a further $5 million from a share purchase plan, primarily to accelerate the commercialisation of its CelGro flagship product.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Orthocell (OCC)

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 29/05/20

1 year TSR5 year TSR
342ndAssetOwl6%4%
536thOrthocell-21%-1%
652ndNeurotech International-41%
729thQueste Communications-56%-26%
671 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

20/11/19
$0 Issued
20/11/19
$0 Issued
21/08/19
$0 Other
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

135th↑Orthocell$1.2m
156th↑Sky and Space Global$503k
159th-AssetOwl$416k
161st↑Neurotech International$246k
162nd↑Queste Communications$246k
197 listed industrial companies ranked by revenue.
Powered by Morningstar ®